Merck, Hit With First Fosamax Verdict, Challenges Plaintiff's Closing Arguments
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm hopes to negate $8 million verdict through post-trial motions.
You may also be interested in...
Merck Wins Second Fosamax Trial After Questioning Qualifications Of Expert Witness
After two bellwether cases, Merck has yet to lose and the next case involves a company-chosen defendant.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.